Oxaliplatin Sun Pharmaceutical Industries Europe B.V. (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapeutic agent used primarily within the colorectal cancer treatment pathway.

• Colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens.
• Gastric cancer: Contributes to disease control in combination chemotherapy protocols.
• Pancreatic cancer: Used off‑label in some combination regimens to improve response rates.

• Oxaliplatin forms reactive platinum complexes that covalently bind to DNA, creating intra‑ and interstrand cross‑links that inhibit DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells.

Adverse reactions to oxaliplatin may vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: Frequently reported during or after infusion.
• Peripheral neuropathy: Tingling or numbness, often dose‑related.
• Diarrhoea: May range from mild to moderate severity.
• Fatigue: Generalised tiredness experienced during treatment cycles.
• Myelosuppression: Reduced blood cell counts, increasing infection risk.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: Including anaphylaxis and bronchospasm.
• Acute neurotoxicity: Sudden onset of muscle cramps or respiratory difficulty.
• Cardiotoxicity: Rare arrhythmias or myocardial injury.
• Hemolytic‑uremic syndrome: Extremely rare but potentially life‑threatening.
• Tumour lysis syndrome: May occur in high‑burden disease settings.

When handling oxaliplatin, clinicians and patients should observe several safety measures.

• Renal function monitoring: Assess creatinine clearance before each cycle.
• Neuropathy assessment: Evaluate sensory changes regularly to adjust dosing.
• Hematologic monitoring: Perform complete blood counts prior to infusion.
• Hypersensitivity vigilance: Observe for signs of allergic reaction during administration.
• Pregnancy and lactation: Contra‑indicated unless benefits outweigh risks; discuss with obstetric specialist.
• Store at below 25°C: Keep in original packaging, protect from light and moisture.

Oxaliplatin may interact with other agents, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Anticoagulants: Increased bleeding risk when combined with oxaliplatin.
• High‑dose vitamin C: May reduce platinum‑induced cytotoxicity.

Moderate Interactions (Monitor Closely)

• Other neurotoxic chemotherapy (e.g., paclitaxel): Heightened peripheral neuropathy.
• Renal‑clearing drugs (e.g., cisplatin): Cumulative nephrotoxicity potential.
• Immunosuppressants: Enhanced infection susceptibility.
• Proton pump inhibitors: Possible alteration of drug excretion.
• Herbal supplements (e.g., St. John’s wort): May affect metabolic pathways.